País: Irlanda
Idioma: anglès
Font: HPRA (Health Products Regulatory Authority)
A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A A/VICTORIA/361/2011 (H3N2) - DERIVED STRAIN USED IVR-165 B/MASSACHUSETTS/2/2012
Sanofi Pasteur MSD Ltd
A/CALIFORNIA/7/2009 (H1N1)PDM09 - DERIVED STRAIN USED NYMC X-179A A/VICTORIA/361/2011 (H3N2) - DERIVED STRAIN USED IVR-165 B/MAS
7.5 mcg ea %v/v
Suspension for Injection
Product subject to prescription which may not be renewed (A)
Withdrawn
2014-09-05
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Inactivated Influenza Vaccine (Split Virion) for Paediatric use, suspension for injection in prefilled syringe. Influenza vaccine (split virion, inactivated). 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Influenza virus (inactivated, split) of the following strains*: • A/California/7/2009 (H1N1)pdm09-derived strain used (NYMC X-179A) 7.5 micrograms HA** • A/Texas/50/2012 (H3N2)-derived strain used (NYMC X-223A).......... ...7.5 micrograms HA** • B/Massachusetts/2/2012............................................................................. 7.5 micrograms HA** Per 0.25 ml dose * propagated in fertilised hens’ eggs from healthy chicken flocks ** haemagglutinin This vaccine complies with the WHO recommendations (Northern Hemisphere) and EU decision for the 2014/2015 season. For a full list of excipients, see section 6.1. Inactivated Influenza Vaccine (Split Virion) for Paediatric Use may contain traces of eggs, such as ovalbumin, and of neomycin, formaldehyde and octoxinol-9, which are used during the manufacturing process (see section 4.3). 3 PHARMACEUTICAL FORM Suspension for injection in prefilled syringe. The vaccine, after shaking gently, is a slightly whitish and opalescent liquid. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of influenza, especially in those who run an increased risk of associated complications. Inactivated Influenza Vaccine (Split Virion) For Paediatric Use is indicated in children from 6 to 35 months of age. The use of Inactivated Influenza Vaccine (Split Virion) For Paediatric Use should be based on official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Children from 6 months to 35 months: clinical data are limited. Dosages of 0.25 ml or 0.5 ml may be given. The dos Llegiu el document complet